Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer

Summary

The primary objective is to estimate the time to progressive disease for patients who receive LY573636-sodium (hereafter referred to as LY573636) after two previous treatments for metastatic non-small cell lung cancer. Patients will receive an intravenous infusion of study drug once every 21 days. Computed tomography (CT)-scans will be done before the first dose and then after every other treatment.

Timeline

Start

2006-09

Primary completion

2008-10

Completion

2008-10

Drugs

Indications